Hepatic steatosis in chronic hepatitis C: Impact on response to anti-viral treatment with peg-interferon and ribavirin

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 10, 2005, Pages 943-949

  Guidi, M ^a,b   Muratori, P ^a   Granito, A ^a   Muratori, L ^a   Pappas, G ^a   Lenzi, M ^a   Bianchi, F B ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICROSOME ANTIBODY; MITOCHONDRION ANTIBODY; PEGINTERFERON ALPHA2B; RIBAVIRIN; SMOOTH MUSCLE ANTIBODY; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 27744534294     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02679.x     Document Type: Article

References (59)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-32.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
4. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-S56.
5. Shiffman ML. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. Liver Transpl 2003; 9: S14-S20.
6. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24(Suppl. 2): 3-8.
7. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
8. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30(Suppl. 1): S77-S84.
9. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
10. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 2004; 24: 399-413.
11. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
12. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-34.
13. Petit JM, Benichou M, Duvillard L, et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003; 98: 1150-4.
14. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.
15. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.
16. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
17. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.
18. Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
19. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837-42.
20. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.
21. Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001; 16: 190-5.
22. Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and nonalcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38: 705-9.
23. Lam NP, DeGuzman LJ, Pitrak D, Layden TJ. Clinical and histologic predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection. Dig Dis Sci 1994; 39: 2660-4.
24. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
25. Harrison SA, Brunt EM, Qazi RA, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3: 604-9.
26. Fabris P, Floreani A, Carlotto A, et al. Impact of liver steatosis on virological response in elderly Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin. Aliment Pharmacol Ther 2005; 21: 1173-8.
27. Akuta N, Suzuki F, Suzuki Y, et al. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2 a: virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005; 75: 550-8.
28. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
29. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001; 35:307.
30. Kaserer K, Fiedler R, Steindl P, Muller CH, Wrba F, Ferenci P. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology 1998; 32: 454-61.
31. Bjoro K, Bell H, Helium KB, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37: 226-32.
32. Ziol M, Nhieu JT, Roudot-Thoraval F, et al. A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C. J Hepatol 1996; 25: 833-41.
33. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
34. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
35. Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-83.
36. Muratori P, Muratori L, Guidi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005; 40: 501-7.
37. Fiore G, Fera G, Napoli N, Vella F, Schiraldi O. Liver steatosis and chronic hepatitis C: a spurious association? Eur J Gastroenterol Hepatol 1996; 8: 125-9.
38. Wong VS, Wight DG, Palmer CR, Alexander GJ. Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model. J Clin Pathol 1996: 49: 465-9.
39. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198-206.
40. Giannini E, Ceppa P, Botta F, et al. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. Liver 1999; 19: 432-7.
41. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001: 21: 266-71.
42. Monto A, Alonzo J. Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-36.
43. Sharma P, Balan V, Hernandez J, et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci 2004; 49: 25-9.
44. Hui JM. Kench J, Farrell GC, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873-81.
45. Ramalho F. Hepatitis C virus infection and liver steatosis. Antiviral Res 2003; 60: 125-7.
46. Hezode C. Roudot-Thoraval F, Zafrani ES, Dhumeaux D. Pawlotsky JM. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004; 11: 455-8.
47. Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 2005; 40: 329-36.
48. Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D. Pawlotsky JM. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol 2005; 100: 711-5.
49. Tsutsumi T, Suzuki T, Shimoike T, et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002; 35: 937-46.
50. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002; 292: 198-210.
51. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78: 1527-31.
52. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94: 1200-5.
53. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Faseb J 2002; 16: 185-94.
54. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
55. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-65.
56. Emerit I, Serejo F, Filipe P, et al. Clastogenic factors as biomarkers of oxidative stress in chronic hepatitis C. Digestion 2000; 62: 200-7.
57. De Maria N, Colantoni A, Fagiuoli S, et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996; 21: 291-5.
58. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.
59. Fujie H, Yotsuyanagi H, Moriya K. et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999; 59: 141-5.